Evidence map›Paper›PMID 37381778›Full record

ArticleHaematologica2023

Amyloidogenic light chains impair plasma cell survival.

Marjorie Pick, Eyal Lebel, Sharona Elgavish, Hadar Benyamini, Yuval Nevo, Rachel Hertz, Jacob Bar-Tana, Paola Rognoni, Giampaolo Merlini, Moshe E Gatt

Open access · goldAbstract read
In one paragraph

Article in Haematologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. The molecular landscape of AL amyloidosis.British journal of haematology · 2025
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Marjorie PickDepartment of Hematology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem. marjorie@cc.huji.ac.il.
Eyal LebelDepartment of Hematology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem.
Sharona ElgavishInfo-CORE, I-CORE Bioinformatics Unit of the Hebrew University of Jerusalem.
Hadar BenyaminiInfo-CORE, I-CORE Bioinformatics Unit of the Hebrew University of Jerusalem.
Yuval NevoInfo-CORE, I-CORE Bioinformatics Unit of the Hebrew University of Jerusalem.
Rachel HertzSchool of Public Health, Hebrew University of Jerusalem.
Jacob Bar-TanaSchool of Public Health, Hebrew University of Jerusalem.
Paola RognoniAmyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia.
Giampaolo MerliniAmyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia.
Moshe E GattDepartment of Hematology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem.
Hebrew University of Jerusalem · ILUniversity of Pavia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Systemic light chain amyloidosis (AL) is a clonal plasma cell disorder characterized by the deposition of misfolded immunoglobulin light chains (LC) as insoluble fibrils in organs. The lack of suitable models has hindered the investigation of the disease mechanisms. Our aim was to establish AL LC-producing plasma cell lines and use them to investigate the biology of the amyloidogenic clone. We used lentiviral vectors to generate cell lines expressing LC from patients suffering from AL amyloidosis. The AL LC-producing cell lines showed a significant decrease in proliferation, cell cycle arrest, and an increase in apoptosis and autophagy as compared with the multiple myeloma LC-producing cells. According to the results of RNA sequencing the AL LC-producing lines showed higher mitochondrial oxidative stress, and decreased activity of the Myc and cholesterol pathways. The neoplastic behavior of plasma cells is altered by the constitutive expression of amyloidogenic LC causing intracellular toxicity. This observation may explain the disparity in the malignant behavior of the amyloid clone compared to the myeloma clone. These findings should enable future in vitro studies and help delineate the unique cellular pathways of AL, thus expediting the development of specific treatments for patients with this disorder.

Indexed as

AmyloidosisImmunoglobulin Light-chain AmyloidosisMultiple MyelomaAmyloidCell SurvivalHumansImmunoglobulin Light ChainsPlasma CellsAmyloidImmunoglobulin Light Chains

Identifiers

PMID37381778
PMCPMC10690890
OpenAlexW4382501747

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.